Hostname: page-component-7479d7b7d-t6hkb Total loading time: 0 Render date: 2024-07-12T02:03:42.333Z Has data issue: false hasContentIssue false
  • English
  • Français

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and antipsychotic-induced metabolic disturbances in first-episode schizophrenia patients

Published online by Cambridge University Press:  23 March 2020

B. Misiak ,
Ł. Łaczmański ,
K. Słoka ,
E. Szmida ,
R. Ślęzak ,
P. Piotrowski ,
A. Kiejna  and
D. Frydecka
B. Misiak*
Affiliation:
Wroclaw Medical University, Department of Psychiatry, Wroclaw, Poland
Ł. Łaczmański
Affiliation:
Wroclaw Medical University, Department of Endocrinology and Diabetology, Wroclaw, Poland
K. Słoka
Affiliation:
Wroclaw Medical University, Department of Endocrinology and Diabetology, Wroclaw, Poland
E. Szmida
Affiliation:
Wroclaw Medical University, Department of Genetics, Wroclaw, Poland
R. Ślęzak
Affiliation:
Wroclaw Medical University, Department of Genetics, Wroclaw, Poland
P. Piotrowski
Affiliation:
Wroclaw Medical University, Department of Psychiatry, Wroclaw, Poland
A. Kiejna
Affiliation:
Wroclaw Medical University, Department of Psychiatry, Wroclaw, Poland
D. Frydecka
Affiliation:
Wroclaw Medical University, Department of Psychiatry, Wroclaw, Poland
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There is a scarcity of prospective studies addressing the influence of the methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms on antipsychotic-induced metabolic changes in first-episode schizophrenia (FES) patients.

Objectives

We aimed at investigating metabolic side effects of second-generation antipsychotics (SGAs) with respect to the MTHFR gene polymorphisms in FES patients.

Methods

Polymorphisms in the MTHFR gene (C677T and A1298C) were investigated with respect to changes in body mass index (BMI) and waist circumference (WC) together with serum levels of glucose, lipids, homocysteine, vitamin B12 and folate after 12 weeks of treatment with SGAs in 135 FES patients.

Results

The 677TT genotype was associated with significantly higher BMI, WC and serum levels of triglycerides, as well as significantly lower folate levels at baseline. Additionally, the 677T allele was associated with significantly lower folate levels at baseline. The 677CC homozygotes had significantly higher increase in BMI and serum levels of triglycerides. The 677TT genotype predicted significantly higher increase in homocysteine levels and significantly higher decrease in folate levels. These associations were also significant in the allelic analysis. Only the patients with the 677T allele had significantly lower folate levels and significantly higher homocysteine levels at the follow-up. The 677T allele was also related to significantly lower increase in WC. The 1298CC homozygotes had significantly higher weight gain in the course of treatment with SGAs.

Conclusions

The MTHFR gene polymorphisms might predict antipsychotic-induced weight gain in FES patients. In addition, the MTHFR C677T polymorphism might be also predictive with respect to other metabolic adversities of SGAs.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
FC82
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S104
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.